

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement by Applicant	ATTY. DOCKET NO. WAX017-185360C	SERIAL NO 10/715,166 To Be Assigned
	APPLICANT Zhang, Ting-Dong	
	FILING DATE To Be Assigned	GROUP 1616 To Be Assigned

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
<i>SD</i>	95/01789	1/19/95	WO - PCT			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)


<i>SD</i>			Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages by Noburu Ishinishi, Masako Tomita and Akira Hisanaga at the Department of Hygiene, Faculty of Medicine, Kyushu University, Fukuoka, Japan, <i>Fukuoka Acute Medicine, 12:170, 1980.</i>
<i>SD</i>			Suehiro Shimotsuura, Studies on the Antineoplastic Actions of As ₂ O ₃ by Department of Pharmacology, Tokyo Dental College (1986) (English Translation), <i>Shikwa Gakuho, Vol. 86, Pages 1237-1253</i>
<i>SD</i>			IPCS International Programme on Chemical Safety, Environmental Health Criteria 18 - Arsenic, published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization - World Health Organization, Geneva, pp. 76-146, 1981
<i>SD</i>			IPCS International Programme on Chemical Safety Health and Safety Guide No. 70 - Inorganic Arsenic Compounds Other Than Arsenic Health and Safety Guide - World Health Organization, Geneva 1992
<i>SD</i>			Huang, S.L. et al., Chinese J. Hematol., Vol. 16, 1995, pages 26-28

Examiner <i>SD</i>	Date Considered 6/30/05
-----------------------	----------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement by Applicant (Rev. 2-32)	ATTY. DOCKET NO. WAX017-185360C	SERIAL NO 10/715,166 To Be Assigned
	APPLICANT Zhang, Ting-Dong	
	FILING DATE To Be Assigned	GROUP 1616 To Be Assigned


D		Kwong, Y.L. et al., "Delicious Poison: Arsenic Trioxide for the treatment of Leukemia," Blood, Vol. 89(9), 1997, pages 3487-3488.
		Shen, Zhi-Xiang et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the treatment of Acute Promyelocytic Leukemia (APL) . . ." Blood, Vol. 89(9), 1997, page 3354.
		Fluka 1995/96 Catalog, page 152-153 - July, 1995.
		USP dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville, MD, page 59. November, 1994
		Zhang Peng et al., "Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide," Chinese Journal of Hematology, Vol. 17, No. 2, pages 58-60. February, 1996
		Guo-Qiang Chen et al., "In vitro studies on cellular and molecular mechanisms of arsenic trioxide . . ." Blood, Vol. 88, No. 3, pages 1052-61. August 1, 1996
		Shibuya, "Experimental arsenous oxide poisoning," Tokyo Jikeikai Ika Daigaku Zasshi, Vol. 86, No. 4, pages 563-75. 1971
		Reichl et al., "Effect of arsenic on cellular metabolism after single or repeated injection in guinea pigs," Arch. Toxicol., Suppl. 13, pages 363-65. 1989
		Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, pages 1570-80. 1990
		Arsenic, Environmental Health Criteria 18, Geneva: WHO, 1981
		Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide Health and Safety Guide No. 70, WHO, Geneva, 1992
D		Ishinishi N. et al. Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages. Fukuoka Acta Medicine, 71(1); 27-40, 1980

Examiner 	Date Considered 6/30/05
---	----------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement by Applicant (Rev. 2-32)	ATTY. DOCKET NO. WAX017-185360C	SERIAL NO 101715,166 To Be Assigned
	APPLICANT Zhang, Ting-Dong	
	FILING DATE To Be Assigned	GROUP To Be Assigned 1616

D			The Merck Index, 10th ed., Rahway (NJ), Merck & Co., Inc., 1983, page 117, entry 824
			Sun H.D. et al. The Therapeutical Effect of Ailing No. 1 (As ₂ O ₃) on 32 cases with acute promyelocytic leukemia (APL). Chinese Union Journal of Traditional Medicine and Western Medicine, 12:170, 1992
			Shimotsoura, S. et al., "Studies on the antineoplastic actions of As ₂ O ₃ ," Shikwa Gakuho, Vol. 86, pages 1237-1253 (Original article in Japanese), 1986.
			Venditti J.M., The National Cancer Institute Antitumor Drug Discovery Program, Current and Future Perspectives. A Commentary, Cancer Treatment Reports Vol. 67, No. 9, September, 1983
			Chemical Abstracts 130: 115060, 1999
			Zhang Peng et al., "APL Treatment with '713' - Clinical observation on 117 cases and mechanism study," The Academic Journal of Harbin Medical University, Issue 3, page 243, June, 1995 (English Translation)
			Zhang T. et al., "Clinical Analysis and Experimental Research on Ai-Ling I Medicine in Treating Acute Granulocytic Leukemia, Chinese & Western Medicines Magazine, Vol. 4, No. 1, 1984 (English Translation)
			Chinese Medical Association, Heilongjiang Branch, "Letter on Historical Facts Regarding the Development of 'Ai Ling No. 1' and the Clinical Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia and a Study of Its Mechanism," March 27, 1998 (English Translation)
			The Merck Index, 10th ed., Merck & Co., Rahway (NJ), 1983, page 1098, item #7479
D			Forkner, C.E. et al., "Arsenic as a therapeutic agent in chronic myelogenous leukemia," The Journal of the American Medical Association, Vol. 97, No. 1, July 4, 1931, pages 3-5

Examiner 	Date Considered 6/30/05
---	----------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.